## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the above-referenced application.

Listing of Claims:

1–23 **(Cancelled)**

24. **(New)** A method for treating pain in a mammal, said method comprising administering to said mammal a chimeric peptide comprising an agonist opioid receptor binding moiety at its N-terminus and an agonist Substance P receptor binding moiety at its C-terminus, in an amount sufficient to induce analgesia in said mammal.

25. **(New)** The method of claim 24 wherein, in the peptide, the agonist opioid receptor binding moiety is a μ, δ or κ agonist opioid receptor binding moiety.

26. **(New)** The method of claim 25 wherein, in the peptide, the agonist opioid receptor binding moiety is a μ agonist opioid receptor binding moiety.

27. **(New)** The method of claim 26 wherein, in the peptide, the N-terminal amino acid residue of said opioid receptor binding moiety is a free amine.

28. **(New)** The method of claim 27 wherein, in the peptide, the N-terminal amino acid residue of said opioid receptor binding moiety is Tyr.

29. **(New)** The method of claim 28 wherein, in the peptide, said opioid receptor binding moiety is a peptide having any one of SEQ ID Nos: 1-11, or N-terminal fragment thereof.

30. **(New)** The method of claim 28 wherein, in the peptide, said opioid receptor binding moiety is endomorphin 1, endomorphin 2, or N-terminal fragment thereof.

31. **(New)** The method of claim 30 wherein, in the peptide, said opioid receptor binding moiety is a peptide having SEQ ID No: 2 or 3, or N-terminal fragment thereof.

32. **(New)** The method of claim 26 wherein, in the peptide, said agonist Substance P receptor binding moiety comprises Substance P, or C-terminal Substance P fragment thereof.

33. **(New)** The method of claim 26 wherein, in the peptide, the –COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is protected.

34. **(New)** The method of claim 33 wherein, in the peptide, the –COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is amidated.

35. **(New)** The method of claim 34 wherein, in the peptide, the C-terminal amino acid residue of said Substance P receptor binding moiety is Met-$NH_2$.

36. **(New)** The method of claim 35 wherein, in the peptide, said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 21, 36 and 38-41, or C-terminal fragment thereof.

37. **(New)** The method of claim 26 wherein, in the peptide, the opioid receptor binding moiety is endomorphin 1, endomorphin 2, or N-terminal fragment thereof; and the Substance P receptor binding moiety is Substance P, or C-terminal fragment thereof.

38. **(New)** The method of claim 26 wherein the peptide has SEQ ID No: 42.

39. **(New)** The method of claim 26 wherein the peptide has SEQ ID No: 43.

40. **(New)** The method of claim 24 wherein the method of administration is selected from the group consisting of intrathecal, intracerebroventricular and systemic administration.

41. **(New)** The method of claim 24 wherein the peptide is administered with a solubilizing agent.

42. **(New)** The method of claim 41 wherein the solubilizing agent is cyclodextran.